Myriad Genetics (MYGN +2.8%) is up, albeit on below-average volume, on the heels of a new analysis from the GUIDED clinical trial using a depression scale called HAM-D6. The results were just published online in BMC Psychiatry.
The key takeaways were statistically significant improvements in remission, response and symptoms in GeneSight-guided care at week 8 compared with standard treatment.
GUIDED was a large prospective study aimed at assessing the benefit of pharmacogenomics-guided treatment for depression using the GeneSight Psychotropic test compared to an active therapy control arm.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.